ArticleClinical drug investigation2014

Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.

Carla Rognoni et al.PubMed ↗Publisher ↗

No numbers read from the abstract.